<?xml version="1.0" encoding="UTF-8"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-10-19T04:52:13Z</responseDate><request verb="GetRecord" identifier="oai:ebyu-rdlopen.rawdatalibrary.net:ebyu/13136" metadataPrefix="oai_dc">https://ebyu-rdlopen.rawdatalibrary.net/oai/request</request><GetRecord><record><header><identifier>oai:ebyu-rdlopen.rawdatalibrary.net:ebyu/13136</identifier><datestamp>2026-10-18T21:13:05Z</datestamp><setSpec>openaire</setSpec><setSpec>driver</setSpec><setSpec>com_ebyu_10000</setSpec><setSpec>col_ebyu_10001</setSpec></header><metadata><oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"><dc:title>Protection against experimental cisplatin-induced optic nerve toxicity using resveratrol: A rat model study</dc:title><dc:creator>Agcayazi, Sümeyye Burcu</dc:creator><dc:creator>Ugurlu, Adem</dc:creator><dc:creator>Ucak, Turgay</dc:creator><dc:creator>Tasli, Nurdan Gamze</dc:creator><dc:creator>Karakurt, Yucel</dc:creator><dc:creator>Icel, Erel</dc:creator><dc:creator>Keskin Cimen, Ferda</dc:creator><dc:creator>Süleyman, Halis</dc:creator><dc:subject>cisplatin</dc:subject><dc:subject>optic nerve</dc:subject><dc:subject>Resveratrol</dc:subject><dc:subject>toxicity</dc:subject><dc:subject>Animals</dc:subject><dc:subject>Disease Models, Animal</dc:subject><dc:subject>Humans</dc:subject><dc:subject>Male</dc:subject><dc:subject>Neuroprotective Agents</dc:subject><dc:subject>Optic Nerve Injuries</dc:subject><dc:subject>Oxidative Stress</dc:subject><dc:subject>Rats</dc:subject><dc:subject>antioxidant</dc:subject><dc:subject>glutathione</dc:subject><dc:subject>immunoglobulin enhancer binding protein</dc:subject><dc:subject>malonaldehyde</dc:subject><dc:subject>oxidizing agent</dc:subject><dc:subject>thiopental</dc:subject><dc:subject>tumor necrosis factor</dc:subject><dc:subject>neuroprotective agent</dc:subject><dc:subject>animal experiment</dc:subject><dc:subject>animal model</dc:subject><dc:subject>animal tissue</dc:subject><dc:subject>antiinflammatory activity</dc:subject><dc:subject>antioxidant activity</dc:subject><dc:subject>Article</dc:subject><dc:subject>bleeding</dc:subject><dc:subject>blood vessel injury</dc:subject><dc:subject>blood vessel occlusion</dc:subject><dc:subject>capillary proliferation</dc:subject><dc:description>Aim: To investigate the effects of resveratrol on oxidative stress and inflammation parameters and histological alterations in cisplatin-induced optic nerve damage in a mouse model. Material and Method: Thirty-six albino Wistar male rats were divided into three groups as control, 5 mg/kg cisplatin-administered (Cis) and 5 mg/kg cisplatin + 25 mg/kg resveratrol-administered (Cis + Res) animals. At the end of the experimental period, the rats were sacrificed with high-dose (50 mg/kg) thiopental sodium, and their optic nerves were dissected. Malondialdehyde (MDA), total glutathione (tGSH), total oxidant status (TOS), total antioxidant status (TAS), tumour necrosis factor alpha (TNF-α), nuclear factor kappa B (NF-KB) levels, and histopathological findings were assessed using the optic nerve tissues. Results: In the Cis + Res group, the MDA, TOS, OSI, TNF-a and NFK-B levels were significantly lower and the tGSH and TAS levels were significantly higher compared with the Cis group (P = 0.001). In histological evaluations, there were dilated and congested blood vessels, destruction, oedema, degeneration, haemorrhage, and proliferating capillaries indicating the presence of inflammation and damage only in the Cis-administered group. However, in the Cis + Res group, the histological findings were very similar to the healthy controls. Conclusion: Resveratrol is a promising neuroprotective agent for cisplatin-induced optic nerve toxicity with its anti-oxidant and anti-inflammatory effects. Further investigations are needed to evaluate the possible therapeutic effects on other optic nerve toxicities. © 2021 Informa UK Limited, trading as Taylor &amp; Francis Group.</dc:description><dc:publisher>Taylor and Francis Ltd.</dc:publisher><dc:date>2021</dc:date><dc:type>Article</dc:type><dc:identifier>https://rdlopen.rawdatalibrary.net/r/ebyu/13136</dc:identifier><dc:identifier>https://doi.org/10.1080/15569527.2021.1940195</dc:identifier><dc:identifier>1556-9527</dc:identifier><dc:language>en</dc:language><dc:relation>Cutaneous and Ocular Toxicology</dc:relation><dc:rights>info:eu-repo/semantics/openAccess</dc:rights><dc:type>info:eu-repo/semantics/article</dc:type><dc:identifier>https://ebyu-rdlopen.rawdatalibrary.net/tr/items/ebyu/13136</dc:identifier></oai_dc:dc></metadata></record></GetRecord></OAI-PMH>